Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The **N20 blocking peptide** is a synthetic peptide that specifically blocks the binding between **CRIPTO** (also known as TDGF1) and **GRP78** (Glucose-Regulated Protein 78, also known as HSPA5), thereby inhibiting CRIPTO/GRP78-dependent signaling. This pathway is implicated in promoting aggressive tumor phenotypes and chemoresistance in hepatocellular carcinoma and potentially other cancers. By blocking CRIPTO/GRP78 interaction, the N20 peptide reduces downstream AKT signaling and enhances tumor responsiveness to agents such as sorafenib. The peptide is used in research settings to evaluate CRIPTO signaling dependency and therapeutic modulation in cancer models[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N20 blocking peptide.